#YonhapInfomax #SamsungBiologics #LaborStrike #WageNegotiations #CDMOOperations #UnionVote #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=112659
If the two sides continue to fail to reach an agreement, the union will begin collective action on May 21, followed by a full general strike on May 1, ...
Samsung Biologics faces its first strike since founding as 95.5% of union voters back walkout, threatening the company's 15 trillion won CDMO expansion strategy amid global competition.#SamsungBiologics #strike #laborunion #CDMO #biopharmaceutical #collectivebargaining #wagenegotiation #SamsungGroup
Samsung Biologics Faces First Strike in 15-Year History
The union plans, should the vote approve strike action, to begin collective action on May 21 and escalate to a full-scale general strike on May 1, ...
Samsung Biologics faces its first-ever strike as union members overwhelmingly vote on industrial action after 13 rounds of failed wage negotiations, with workers demanding 14% pay raises amid record earnings.#SamsungBiologics #laborstrike #wagenegotiations #CDMO #biopharmaceutical #unionvote #SamsungGroup #collectivebargaining
Samsung Biologics Faces First-Ever Strike as 95% of Union Members Vote

Samsung Biologics strengthens CDMO competitiveness by internalizing MCB production and vector construction services, enabling nine-month timeline from vector construction to IND submission while enhancing IP protection and reducing development periods through elimination of third-party transfers

Samsung Biologics announces 520 billion won capital injection into its U.S. subsidiary to fund acquisition of Human Genome Sciences' biopharmaceutical production facility in Rockville, Maryland, through shareholder allocation with record date set for the 27th.

Samsung Biologics CEO John Rim, reappointed for a third term, pledges to accelerate expansion in production capacity, portfolio diversification, and global presence despite challenging market conditions, while advancing U.S. plant acquisition and domestic bio campus construction.

Samsung Biologics has completed third-party verification of its product carbon footprint system, bolstering ESG management as global clients demand stricter carbon neutrality standards.